Aigen Investment Management LP Purchases 7,867 Shares of Insmed Incorporated (NASDAQ:INSM)

Aigen Investment Management LP grew its position in Insmed Incorporated (NASDAQ:INSM) by 193.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,936 shares of the biopharmaceutical company’s stock after acquiring an additional 7,867 shares during the quarter. Aigen Investment Management LP’s holdings in Insmed were worth $824,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Proficio Capital Partners LLC bought a new stake in Insmed in the 4th quarter worth approximately $1,864,000. M&T Bank Corp increased its stake in Insmed by 5.6% in the 4th quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company’s stock worth $217,000 after acquiring an additional 166 shares during the last quarter. Atria Investments Inc increased its stake in Insmed by 5.0% in the 4th quarter. Atria Investments Inc now owns 5,232 shares of the biopharmaceutical company’s stock worth $361,000 after acquiring an additional 247 shares during the last quarter. Assetmark Inc. increased its stake in Insmed by 1.1% in the 4th quarter. Assetmark Inc. now owns 26,344 shares of the biopharmaceutical company’s stock worth $1,819,000 after acquiring an additional 291 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Insmed by 7.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,546,607 shares of the biopharmaceutical company’s stock worth $106,778,000 after acquiring an additional 102,341 shares during the last quarter.

Insmed Trading Up 0.4 %

Shares of NASDAQ INSM opened at $77.55 on Thursday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market capitalization of $14.04 billion, a P/E ratio of -13.87 and a beta of 1.11. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The business has a fifty day moving average price of $75.46 and a 200 day moving average price of $73.84.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Equities research analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on INSM shares. JPMorgan Chase & Co. lifted their price objective on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Wells Fargo & Company boosted their target price on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Royal Bank of Canada initiated coverage on Insmed in a research report on Tuesday, February 25th. They set an “outperform” rating and a $100.00 target price on the stock. Finally, Guggenheim reissued a “buy” rating and set a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, Insmed presently has an average rating of “Moderate Buy” and an average price target of $91.60.

Insider Activity at Insmed

In related news, CEO William Lewis sold 2,978 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.36, for a total transaction of $188,686.08. Following the transaction, the chief executive officer now directly owns 392,589 shares of the company’s stock, valued at $24,874,439.04. This represents a 0.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Martina M.D. Flammer sold 3,344 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total value of $220,403.04. Following the transaction, the insider now directly owns 102,766 shares in the company, valued at $6,773,307.06. This represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 550,957 shares of company stock valued at $42,859,028 in the last ninety days. Corporate insiders own 4.60% of the company’s stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.